| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6135956 | Microbes and Infection | 2012 | 6 Pages |
Abstract
This article reviews current knowledge about respiratory syncytial virus (RSV) binding and entry into cells. The recent discovery of Nucleolin as a fusion receptor for RSV opens new avenues for developing interventions, while raising questions concerning RSV pathobiology and tropism. We also discuss characteristics of a good RSV drug target.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Peter Mastrangelo, Richard G. Hegele,